MEDVi vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Willow beats MEDVi overall, scoring 8.2/10 vs 7.7/10. Choose MEDVi for users who want a low entry price with oral and injectable co. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of MEDVi and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

MEDVi

#22 of 48

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake — one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Higher Rated

Willow

#8 of 48

8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	MEDVi	Willow
Our Score	7.7/10	8.2/10
Starting Price	$299/mo	$299/mo
Medication Type	Both	Compounded
Insurance Accepted	No	No
Best For	Users who want a low entry price with oral and injectable compounded options	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#22	#8

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only — no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
−Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out MEDVi with a score of 8.2/10 vs 7.7/10. MEDVi offers both brand-name and compounded medications, giving you more flexibility. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Eden Health GLP-1

$249/mo · 8.9/10 · Both

If neither MEDVi nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Eden Health GLP-1 — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Eden Health GLP-1→Read our full Eden Health GLP-1 review